Diltiazem used for ventricular rate control in patients with atrial fibrillation inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation.
The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?